Background: Data suggest that carvedilol possesses antioxidant properties that might provide vascular protection. We sought to compare the effects of carvedilol and metoprolol tartrate on endothelial function and oxidative stress in a head-to-head trial.
B
eta-adrenergic receptor antagonists (␤-blockers) were shown to be an effective therapy for hypertension, ischemic heart disease, and heart failure. Patients with type 2 diabetes mellitus (T2DM) often have cardiovascular comorbidities that could benefit from ␤-blocker therapy; however, clinicians are often reluctant to utilize this drug class because of reports of worsening glycemic control. 1, 2 The newer, so-called third-generation ␤-blockers may not have these negative glycemic effects. In a randomized controlled trial, carvedilol was shown to have no effect on levels of hemoglobin A1c (HbA1c), whereas treatment with metoprolol resulted in significant increases in this marker of chronic glucose control. 3 These differences are likely related to the unique receptor-blocking actions of these drugs. Carvedilol is a nonselective ␤-receptor antagonist (blocking both ␤ 1 and ␤ 2 receptors) with ␣ 1 -receptor blocking properties, whereas metoprolol is a selective ␤ 1 -receptor antagonist.
Type 2 diabetes mellitus is a coronary-risk equivalent and is associated with hypertension and severe endothelial dysfunction. Therefore, it is important to identify treatments that, in addition to their intended cardiovascular hemodynamic effect, may also improve endothelial health. Studies of ␤-blockers are inconclusive regarding their effects on endothelial function, with some studies showing some benefit, 4 -6 and others demonstrating no effect. 7, 8 There is evidence to suggest that two of the third-generation ␤-blockers, carvedilol and nebivolol, contain vasodilating properties that are likely mediated through an increased bioavailability of nitric oxide (NO). 9, 10 Both T2DM 11 and hypertension 12 are associated with elevated levels of oxidative stress. Reactive oxygen species uncouple the synthesis of NO and lead to its inactivation, ultimately decreasing NO bioavailability in the vasculature. Therefore, oxidative stress may be one mechanism responsible for endothelial dysfunction in patients with T2DM and hypertension. Data suggest that carvedilol has antioxidant properties, [13] [14] [15] [16] [17] [18] which may provide vascular protection by improving NO bioavailability and therefore endothelial function. No studies to date have examined the effects of carvedilol treatment on endothelial function and oxidative stress in hypertensive patients with T2DM. Therefore, we compared the vascular and antioxidant effects of carvedilol and metoprolol tartrate in a head-tohead trial in patients with T2DM and hypertension.
Methods

Patient Population
Thirty-four patients with clinically diagnosed T2DM and hypertension were randomized to receive either carvedilol or metoprolol tartrate in addition to current antihypertensive medications. Patients were recruited from local Minneapolis and St. Paul medical clinics and via newspaper advertisements. Verbal and written informed consent was obtained from each subject, and the protocol was approved by the Western Institutional Review Board (Olympia, WA). All procedures were conducted in accordance with local institutional and Health Insurance Portability and Accountability Act (HIPAA) guidelines.
Study Design
This was a randomized, double-blind, parallel-group trial that compared the vascular and antioxidant effects of headto-head therapy with either carvedilol or metoprolol in addition to current antihypertensive medications. After baseline testing, patients were randomly assigned to one of two treatment groups for a period of 5 months, after which time retesting occurred. Other concomitant medications known to affect cardiovascular and metabolic risk factors were unchanged throughout the study period.
Treatment Protocol
Carvedilol or metoprolol tartrate was added to current therapy, and was up-titrated to achieve goal blood pressure (systolic, Ͻ135 mm Hg; diastolic, Ͻ85 mm Hg) throughout the entire 5-month treatment period. If the target blood-pressure level could not be reached with the maximal doses of the respective study drugs, then current angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) doses were increased, and, if necessary, a diuretic or a calcium channel blocker was added. The doses of carvedilol were initiated at 6.25 mg twice daily up to a maximal titrated dose of 25 mg twice daily. Metoprolol doses were initiated at 50 mg twice daily up to a maximal titrated dose of 200 mg twice daily. Manual blood-pressure measurements were obtained with a standard sphygmomanometer and were performed in the seated position after at least 10 min of quiet rest. Three consecutive measurements were made, each separated by 2 min. The average of three measurements was calculated. Major exclusion criteria included current ␤-blocker use, HbA1c Ͻ6% or Ͼ9%, screening blood pressure Ͻ130/80, unstable angina, electrocardiogram abnormalities, decompensated heart failure, myocardial infarction in the preceding 3 months, bradycardia, newly diagnosed diabetes (Ͻ3 months), and chronic obstructive pulmonary disease or bronchial asthma. All medications were withheld on the mornings of data collection.
Blood Analyses
Fasting blood was assessed for glucose, insulin, HbA1c, lipids, and C-reactive protein (CRP) at the United Hospital Laboratory (Allina Medical System, St. Paul, MN). Homeostasis-model assessment (HOMA) was used as a marker of insulin resistance and was calculated as (fasting glucose * fasting insulin) ϫ 22.5, as described by Matthews et al. 19 Additional blood was processed, flash-frozen, and stored at Ϫ80°C for later measurement of oxidative stress markers: 8-isoprostane, asymmetric dimethylarginine (ADMA), and oxidized LDL cholesterol. Markers of oxidative stress were measured by ELISA at the University of Minnesota Cytokine Reference Laboratory (Minneapolis, MN). All samples were analyzed in duplicate. The coefficients of variation for oxidative stress markers were as follows: 8-isoprostane, 3.7%; ADMA, 3.4%; and oxidized LDL cholesterol, 3.1%.
Assessment of Vascular Structure and Function
Assessment of brachial and carotid artery structure and function was performed after an overnight fast, using a standard ultrasound machine (Esaote Biomedica, Indianapolis, IN) and an automated wall tracking system (PIE Medical WTS V2; Maastricht, the Netherlands), as previously described. 20, 21 An arterial-pressure waveform was obtained with the use of a tonometer placed over the radial artery and calibrated with a standard blood-pressure cuff placed on the arm. The resting artery diameter, change in diameter throughout the cardiac cycle (for the determination of distension, compliance, and distensibility), and carotid intima-media thickness (cIMT) were measured with the patient in supine position. Flow-mediated, endothelium-dependent dilation (FMD) was induced by releasing a blood-pressure tourniquet around the upper forearm that was inflated for 5 min at a pressure of 250 mm Hg. The change in diameter was tracked starting at cuff release and for 120 sec thereafter. The FMD was expressed as the percent change from the diameter immediately following cuff deflation to the maximal diameter observed during the 2 min after cuff deflation. The reproducibility of this technique in our laboratory shows a mean difference of 0.42% Ϯ 1.5% SD for FMD studies separated by 4 months. 21 At least 10 min after the measurement of FMD, 0.4 mg sublingual nitroglycerin was administered, and the diameter of the brachial artery was measured at 5 min after administration. Endothelium-independent dilation (EID) was defined as the percent change from resting baseline diameter to that obtained at 5 min after nitroglycerin administration.
Statistical Analysis
Sample-size calculations suggested that 16 patients per group would provide Ն80% power to detect statistically significant differences for the main variables of interest: FMD, ADMA, 8-isoprostane, and oxidized LDL cholesterol. Data are presented as mean Ϯ SD. Unpaired t-tests were used to compare the carvedilol and metoprolol groups for baseline variables. Analysis of variance (ANOVA) was used to compare changes in variables between groups before and after the 5-month treatment period. The ANOVA interaction term was the main a priori identified analysis of interest. The alpha value was set at 0.05 to indicate statistical significance. GraphPad Prism version 4.0 (GraphPad Software, Inc., San Diego, CA) and SPSS version 8.0 (SPSS, Inc., Chicago, IL) were used for statistical analyses.
Results
Baseline Characteristics
In total, 36 patients were randomized (carvedilol group, n ϭ 17; metoprolol group, n ϭ 19). Two patients (one from each group) failed to complete the trial because of noncompliance with the study protocol. Overall, patient demographic baseline characteristics were similar. There were no differences between groups for age (carvedilol group, 60.9 Ϯ 8.5 years v metoprolol group, 61.9 Ϯ 9.9 years, P ϭ NS), sex (carvedilol group, 12 men and 4 women v metoprolol group, 12 men and 6 women, P ϭ NS), body mass index (BMI) (carvedilol group, 33.7 Ϯ 5.1 kg/m 2 v metoprolol group, 34.4 Ϯ 6.4 kg/m 2 , P ϭ NS), or waist circumference (carvedilol group, 114.5 Ϯ 7.8 cm v metoprolol group, 118.2 Ϯ 20.1 cm, P ϭ NS).
Medications
Baseline medications were not significantly different between groups. Approximately 75% of patients from both the carvedilol and metoprolol groups were taking an ACE-I and/or ARB, 8% of the carvedilol group and 25% of the metoprolol group were on a calcium channel blocker, and approximately 33% of both groups were taking a diuretic as background antihypertensive therapy prior to enrollment. Fifty percent of the carvedilol group and 66% of the metoprolol group were on statin therapy. A total of 58% of the participants in the carvedilol group and 67% in the metoprolol group were on antidiabetic medications.
Regarding the study drugs, 25% of patients in the carvedilol group were on a maintenance dose of 6.25 mg twice daily, 33% were on a dose of 12.5 mg twice daily, and 42% were on a dose of 25 mg twice daily. For the metoprolol group, 50% were on a maintenance dose of 50 mg twice daily, 33% were on a dose of 100 mg twice daily, and 17% were on a dose of 200 mg twice daily. To achieve target blood pressure during the trial, approximately 8% of the carvedilol group and 17% of the metoprolol group required the addition of a calcium channel blocker, 17% of the carvedilol group required the addition of a diuretic (none in the metoprolol group), and 8% of the metoprolol group required the addition of an ␣-blocker (none in the carvedilol group). For existing medications, approximately 8% of both groups needed an increase in their diuretic regimen, and 33% of the carvedilol group and 8% of the metoprolol group required an increase in their ACE-I/ARB therapy. Overall, there were no statistically significant differences between groups in modifications of hypertensive therapies.
Clinical Variables
Clinical variables are shown in Table 1 . There were no differences between groups at baseline for any of the measured clinical variables. Blood pressure and heart rate were reduced equally in both groups over the treatment period. Their HbA1c was reduced by carvedilol and increased with metoprolol, although this difference did not reach statistical significance (P ϭ .13). Insulin and HOMA were both decreased with carvedilol and increased with metoprolol, even though no significant difference between groups (P ϭ 0.19 and P ϭ .12, respectively) was evident. There was no change in glucose over time or between groups. There were no differences between groups for any of the lipid variables except HDL cholesterol, which significantly decreased in the metoprolol group but did not change in the carvedilol group. This difference between groups was statistically significant (P ϭ .02).
Vascular and Biochemical Variables
All vascular and biochemical data are presented in Table 2 . At baseline, there were no differences between groups for any of the measured variables. Compared with metoprolol, carvedilol significantly improved brachial-artery FMD over time (P Ͻ .001) (Fig. 1) . No differences were observed between groups over time for EID. Because of technical issues, brachial and carotid arterial-stiffness measures were only obtained from 20 patients (carvedilol group, n ϭ 10; metoprolol group, n ϭ 10). There were no differences between groups over time for either brachial or carotid artery distension, compliance, or distensibility. Similarly, no changes were noted between groups over time for cIMT. There were no differences between groups over time for any of the oxidative stress markers (8-isoprostanes, ADMA, and oxidized LDL) or CRP. To evaluate possible mechanisms associated with improved FMD, correlation analyses were performed between changes in FMD and changes in blood pressure, glycemic control, and biomarkers of inflammation or oxidative stress. No significant associations were found among changes in FMD and changes in these variables.
Discussion
The important finding of the current study is that in the presence of equivalent reductions in blood pressure, carvedilol compared with metoprolol significantly improved endothelial function in patients with T2DM and hypertension. These positive changes with carvedilol therapy were not associated with reductions in oxidative stress in this population. The present findings, in conjunction with the previous reports of unaffected glycemic control, suggest that carvedilol is a reasonable choice for reducing blood pressure and improving vascular health in patients with T2DM.
Studies in patient populations other than those with T2DM provided inconclusive and mixed results regarding the effect of ␤-blocker therapy on endothelial function. Matsuda et al 4 reported that compared with placebo, 4 months of carvedilol therapy significantly improved brachial-artery FMD in patients with coronary-artery disease. Similarly, von Zur et al 6 reported improvements in methacholine-stimulated forearm blood flow after 3 months of therapy with either atenolol or the angiotensin receptor blocker irbesartan in patients with hypertension. In a double-blind, controlled, 8-week crossover trial comparing nebivolol plus bendrofluazide versus atenolol plus bendrofluazide, Tzemos et al 5 found that nebivolol significantly increased the forearm vasodilatory response to acetylcholine in patients with hypertension. The vasocon- strictive response to the NO antagonist NG-monomethyl-L-arginne (L-NMMA) was also improved, suggesting increased NO bioavailability and enhanced endothelial function. However, the effect of nebivolol on endothelial function is inconsistent, as Ghiadoni et al reported no improvement in FMD with this therapy. 22 The discrepancy may be related to the different vascular beds in which endothelial function was measured in these two studies (resistance v conduit arteries), or the incompletely understood mechanisms by which nebivolol acts on the vascular wall.
However, despite many of these positive reports, other studies failed to show improvements in endothelial function with ␤-blocker therapy. Higashi et al 7 compared the effects of ACE inhibitors, calcium channel blockers, ␤-blockers, and diuretics on reactive hyperemic forearm blood flow in patients with hypertension. Of all the antihypertensive treatments, only ACE inhibitors improved endothelial function in these patients. Finally, Taddei et al 8 randomized patients with hypertension to either the calcium channel blocker lacidipine or atenolol for 3 months. Lacidipine, but not atenolol, improved acetylcholine-induced forearm blood flow.
We chose to measure three different markers of oxidative stress to evaluate the potential antioxidant effects of carvedilol and to determine if reductions in oxidative stress with this therapy might be a mechanism for improved endothelial function in patients with T2DM. A measure of oxidized arachidonic acid, 8-isoprostane, is a reflection of systemic oxidative stress 23 and is an independent risk marker for coronary heart disease. 24 Asymmetric dimethylarginine is an endogenous inhibitor of NO and is likely a cause or consequence of vascular oxidative stress. 25 Oxidized LDL cholesterol is fundamentally in- volved in the atherosclerotic process and serves as a marker of both systemic and vascular oxidative stress.
Results of the current study indicate that carvedilol does not reduce oxidative stress in patients with T2DM, which suggests that this may not be a mechanism whereby carvedilol improves endothelial function in these patients. The current findings are in agreement with a previous report by Fahlbusch et al, 13 who observed no reductions in 8-isoprostaglandin F2␣ or thiobarbituric acid-reactive substances (TBARS) with 6 days of carvedilol treatment in healthy men. However, our findings are at odds with those of Matsuda et al, 4 who reported a significant reduction in TBARS with carvedilol therapy in patients with coronaryartery disease. These discrepancies might be explained by the different patient populations studied, the varying time courses of treatment, the differing doses of carvedilol utilized, or the concomitant medications used by patients in these studies. In our study, most patients were taking low-to-moderate doses (6.25-12.5 mg twice daily) of carvedilol. Higher doses of carvedilol may, in fact, be associated with reductions in oxidative stress. Other cardiovascular medications, and particularly statins, were shown to reduce levels of oxidative stress. In our sample, the majority (58%) of patients were using a statin during the study, which could have masked any beneficial antioxidant effects of carvedilol. Alternatively, the antioxidant activity of carvedilol may be predominantly intracellular 26 and may not be detectable with the systemic markers of oxidative stress used in the current study. Finally, our study sample may have been too small to detect statistically significant differences in the biomarkers of oxidative stress measured.
One question that remains unanswered by this study relates to the mechanism(s) responsible for the observed improvement in endothelial function. This improvement is probably not related to reductions in blood pressure, because both groups experienced similar decreases in systolic and diastolic blood pressure. Furthermore, no correlations were found between reductions in blood pressure and increases in FMD in our study. Differences in glycemic control between carvedilol and metoprolol might be partially responsible for the improved endothelial function. However, while nonsignificant trends toward reduced insulin, HOMA, and HbA1c were observed, no correlations were found between changes in these variables and improvements in FMD. It is possible that the changes in HDL cholesterol during the study affected the FMD findings. It is well known that HDL cholesterol is closely associated with endothelial function. 27 Although this might explain the decrease in FMD noted in the metoprolol group, it does not explain the improvement observed in the carvedilol group, because HDL levels remained the same. Another possibility is that the alpha-blocking properties of carvedilol might improve endothelial function via peripheral vasodilation. However, in the current study, we were unable to address this potential mechanism. It is possible that carvedilol improves endothelial function through a mechanism not measured in the current study. For example, although we measured CRP levels and did not find a difference, other inflammatory biomarkers may be reduced with carvedilol. Alternatively, it is possible that carvedilol acts directly on the vasculature to increase NO bioavailability and improve endothelial function through currently unknown mechanisms. 9, 10 Two important limitations of this study should be addressed. First, although there were no statistically significant differences between groups for baseline and follow-up antihypertensive medication use, the groups were not perfectly matched in this regard. For example, more patients in the carvedilol group had their existing ACE-I/ARB therapy increased during the course of the trial. This could have confounded the results, because these classes of medications were shown to improve various aspects of vascular health. Second, the current study was not appropriately powered to detect statistically significant differences in some of the measured variables such as HOMA, HbA1c, and cIMT.
In conclusion, the main finding of the current study is that compared with metoprolol, carvedilol significantly improves endothelial function in patients with T2DM and hypertension. No changes were observed for any of the markers of oxidative stress measured in this study (8-isoprostane, ADMA, and oxidized LDL cholesterol). Differences in glycemic control and oxidative stress do not seem to explain the observed improvement in endothelial function, suggesting that other mechanisms may be involved. Because of its beneficial effects on vascular health and its neutral effects on glycemic control, carvedilol may be a preferred antihypertensive therapy compared with other ␤-blocking agents in patients with T2DM.
